AliveDx’s CE mark for the systematic autoimmune rheumatic disease (SARD) assay marks its fifth approval in the past 18 months ...

AliveDx seeks US FDA 510(k) premarket approval for MosaiQ AiPlex CD multiplex microarray: Eysins, Switzerland Tuesday, February 11, 2025, 12:00 Hrs [IST] AliveDx, an established c ...

US FDA grants 510(k) clearance and CLIA waiver to Roche’s cobas liat sexually transmitted infection multiplex assay panels: Basel Thursday, January 23, 2025, 09:00 Hrs [IST] Roc ...

The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...

The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust ...

The following is a summary of “NTHi killing activity is reduced in COPD patients and is associated with a differential ...

The MosaiQ AiPlex CD is designed to improve the  accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows EYSINS, Switzerland , Feb.

Boster Biological Technology advances biotechnology research with its cutting-edge multiplex ELISA service, delivering precision solutions in cytokine assays, custom monoclonal antibodies, and ...

AliveDx has obtained a CE mark under the EU's in vitro diagnostic regulation (IVDR) for the AiPlex connective tissue disease (CTDplus) multiplex assay for use with its MosaiQ planar microarray ...